Welcome to our dedicated news page for Candel Therapeutics (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Candel Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Candel Therapeutics 's position in the market.
Rhea-AI Summary
Candel Therapeutics, a biopharmaceutical company, announced two abstracts accepted for presentation at the 2024 ASCO Annual Meeting. One abstract focuses on a phase 1 clinical trial of CAN-3110 for recurrent high-grade glioma, showcasing feasibility and tolerability. The second abstract presents overall survival data from a phase 2 trial of CAN-2409 plus valacyclovir for NSCLC patients with an inadequate response to front line therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) receives Orphan Drug Designation from the FDA for CAN-2409, a promising multimodal biological immunotherapy candidate for pancreatic cancer. Clinical trial data shows significant improvement in overall survival rates and safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.75%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. presents a first-in-class immunotherapy candidate for solid tumors, inducing tertiary lymphoid structures for improved anti-tumor immunity. The candidate, developed from the enLIGHTEN™ Discovery Platform, shows promising results in inhibiting tumor growth and enhancing response to immune checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.84%
Tags
Rhea-AI Summary
Candel Therapeutics (CADL) announces positive interim data showing significant improvements in overall survival in patients with pancreatic cancer treated with CAN-2409. Survival rates at 24 and 36 months were notably higher in the CAN-2409 group compared to the control group. The treatment was well tolerated with no new safety signals observed. The FDA granted Fast Track Designation for CAN-2409 in combination with valacyclovir for pancreatic cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
280.95%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. announces positive data from ongoing phase 1b clinical trial of CAN-3110 for rHGG patients, showing promising results in overall survival and tolerability. The company received FDA Fast Track Designation for CAN-3110 in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.76%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. reported financial results for Q4 2023, with positive clinical trial outcomes for CAN-2409 in pancreatic cancer and CAN-3110 in high-grade glioma. The company received FDA Fast Track Designations for both treatments, showing improved survival rates compared to standard care. Candel anticipates significant data readouts in 2024 across various cancer platforms, including a potentially registrational phase 3 trial for prostate cancer. Financially, research and development expenses increased due to activities supporting CAN-2409 programs, resulting in a net loss for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) will present a poster at the AACR Annual Meeting on a first-in-class immunotherapy candidate for solid tumors, accelerating the unveiling of the second enLIGHTEN™ program. The presentation focuses on inducing tertiary lymphoid structures as a novel therapeutic strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (CADL) receives FDA Fast Track Designation for CAN-3110, a promising oncolytic viral immunotherapy candidate for recurrent high-grade glioma. Positive results from the phase 1b clinical trial show a nearly doubled median overall survival with a single injection, highlighting the therapy's potential to address the unmet needs in this therapy-resistant condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.5%
Tags
-
Rhea-AI Summary
Candel Therapeutics, Inc. (Nasdaq: CADL) has highlighted upcoming milestones, including data readouts in lung, pancreatic, brain, and prostate cancer, as well as recent successes in immunotherapy. The company received Fast Track Designation from the FDA for its product candidate, CAN-2409, and reported positive clinical trial data for CAN-3110. These developments position Candel for progress and differentiation in the cancer therapeutics market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
Rhea-AI Summary
Candel Therapeutics, Inc. (Candel) (Nasdaq: CADL) has been granted Fast Track Designation by the FDA for its lead investigational adenovirus asset CAN-2409 plus prodrug for the treatment of pancreatic ductal adenocarcinoma (PDAC) to improve overall survival. The company presented encouraging overall survival and immunological biomarker data based on an interim analysis of the randomized, phase 2 clinical trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The estimated survival rate of patients who received the CAN-2409 plus prodrug regimen was 71.4% at both 24 and 36 months, compared to only 16.7% in patients treated with standard of care (SoC) chemoradiation prior to surgery alone. Candel remains on track to release updated overall survival data in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.23%
Tags
Candel Therapeutics, Inc.
Nasdaq:CADL
CADL Rankings
CADL Stock Data
234.19M
18.05M
34.72%
16.46%
0.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
NEEDHAM
About CADL
also known as advantagene. inc., we are a massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our gene mediated cytotoxic (gmci™) platform and our rqnestin34.5 platform. gmci™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.